Abstract 1566P
Background
Participation rate in lung cancer screening (LCS) programs is challenging. The ILYAD (Initiative LYonnaise pour l’Amorçage du Dépistage) study main objective is to assess whereas various communication methods may improve participation rate among a population of eligible staffs of Lyon University Hospital (LUH).
Methods
In a previous work, we assessed the number of eligible employees at LUH. 838 peoples among 26,954 staffs were found eligible to LCS according to current French guidelines. We designed an LCS program dedicated to staffs from LHU. We provided specific email address, phone number, and an online tool. We applied three communication methods for participants recruitment. We started with common displays (flyers, posters) and general emailing. Then, we involved managers of the departments identified with high-risk employees and occupational medicine. Finally, we used specially trained nurses to meet the employees in their daily routine.
Results
From September 2022 to May 2024, 144 participants were included, resulting in a participating rate of 17.2%. 85 (59%) were included during the first period (common displays and emails), 17 (12%) during the second (targeting high-risk), and 44 (30%) during the third (face to face meeting). Institutional general emailing appeared as the best way of recruitment. Surprisingly, face-to-face interaction were not very efficient, principally due to people lack of commitment afterward. During this first round of screening, one positive screening lead to the diagnosis of a stage IA adenocarcinoma. Moreover, we diagnosed 14 early COPD (group A and B). Coronary calcifications were identified in 15 cases. 70% participants contacted us through the online tool.
Conclusions
Despite a population of healthcare employees and different communication strategies tested, our results showed a low LCS participation rate. These results enhanced the fact that population adherence to LCS program will be a critical issue to address properly in order to improve screening efficiency.
Clinical trial identification
Sponsor code: 69HCL22_0466; NCT05452200 N° IDRCB: 2022-A01203-40 Approved by ethic committee CPP OUEST III: 23/06/2022.
Editorial acknowledgement
Legal entity responsible for the study
Hospices Civils de Lyon.
Funding
AstraZeneca Volition Transdiag.
Disclosure
S. Couraud: Financial Interests, Personal and Institutional, Funding, consulting fees: AstraZeneca, Amgen, Boehringer Ingelheim, MSD, Novartis, Sanofi, Roche, Pfizer, BMS; Financial Interests, Institutional, Funding: Chugai, Lilly, Takeda, Janssen, Celgene, Transdiag, Volition, Adene, BD Bioscience; Financial Interests, Personal, Other, consulting fees: Health event, MaaT Pharma, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10